ALPS Advisors’s Nektar Therapeutics NKTR Stock Holding History

ALPS Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.39M	Buy	+34,188	New	+$2.5M	0.01%	467
2019 Q3	–	Sell	-705	Closed	-$376K	–	943
2019 Q2	$376K	Sell	705 -37	-5%	-$18.6K	﹤0.01%	711
2019 Q1	$374K	Sell	742 -692	-48%	-$410K	﹤0.01%	824
2018 Q4	$707K	Sell	1,434 -6	-0.4%	-$3.62K	0.01%	389
2018 Q3	$1.32M	Buy	+1,440	New	+$1.23M	0.01%	313
2018 Q2	–	Sell	-140	Closed	-$223K	–	957
2018 Q1	$223K	Buy	+140	New	+$180K	﹤0.01%	829
2017 Q4	–	Sell	-10,264	Closed	-$3.69M	–	869
2017 Q3	$3.69M	Buy	10,264 +928	+10%	+$290K	0.03%	156
2017 Q2	$2.74M	Buy	+9,336	New	+$2.7M	0.02%	167

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ALPS Advisors's NKTR Position: Q2 2026 in Review

ALPS Advisors opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 34,188 shares worth $2.39M. The stake represents 0.01% of the portfolio and ranks #467 among its holdings. This is a return to the name: ALPS Advisors previously reported a position in NKTR as recently as Q2 2019.

ALPS Advisors first reported a position in NKTR in Q2 2017 and has held it in 8 quarters since. The position peaked at $3.69M in Q3 2017. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

ALPS Advisors held 34,188 shares of Nektar Therapeutics worth $2.39M as of Q2 2026.
Nektar Therapeutics was a new ALPS Advisors position in Q2 2026.
Nektar Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #467 holding.
ALPS Advisors first reported a position in Nektar Therapeutics in Q2 2017 and has held it in 8 quarters since.
ALPS Advisors's Nektar Therapeutics position peaked at $3.69M in Q3 2017.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.